查看购物车
  • Traditional Chinese
  • English
  • Japanese
封面
市场调查报告书
商品编码
1717067

研究抗体和试剂市场（按类型、来源、技术、治疗领域、应用和最终用户划分）—2025 年至 2030 年全球预测

Research Antibodies & Reagents Market by Type, Source, Technology, Disease Area, Application, End User - Global Forecast 2025-2030
出版日期: | 出版商: 360iResearch | 英文 189 Pages | 商品交期: 最快1-2个工作天内

价格

※ 本网页内容可能与最新版本有所差异。详细情况请与我们联繫。

预计到 2024 年研究抗体和试剂市场价值将达到 185.5 亿美元，到 2025 年将达到 207.9 亿美元，复合年增长率为 12.00%，到 2030 年将达到 366.2 亿美元。

主要市场统计数据
基准年2024年 185.5亿美元
预计2025年 207.9亿美元
预测年份 2030 366.2亿美元
复合年增长率（%） 12.00%

抗体和试剂领域持续扩大其对研究、诊断和治疗的影响，推动许多科学学科的创新。近年来，在技术进步和迫切的科学需求的推动下，尤其是在全球健康挑战的背景下，市场发生了显着的转变。这项综合研究旨在探索影响产业的复杂动态，并阐明影响市场行为和策略决策的关键因素。

随着研究人员和组织努力提高其研究的准确性和可靠性，具有更高特异性和可重复性的新产品和新方法正在出现。本摘要所依据的研究深入探讨了产品细分、技术突破和不断变化的用户需求，为相关人员提供了可直接应用于业务和策略框架的可行见解。

该报告基于严格的市场分析和广泛的区域研究数据，提供了当前趋势的全球概述。它强调了发展的方面和商业性方面，以及如何调整正在进行的研究工作以应对现代生物医学探索的复杂挑战。本介绍为更深入地讨论市场转变和细分洞察铺平了道路，这些转变和洞察将影响未来几年抗体和试剂行业的发展轨迹。

一场变革将重新定义抗体和试剂市场

在技​​术快速创新的时代，抗体和试剂市场正在经历一场重新定义产品开发和市场进入的转型转变。传统研究方法与最尖端科技的结合正在加速重组工程、配方优化和先进分析等领域的创新。这些发展正在彻底改变产品在研发和临床环境中的创造、评估和最终部署方式。

现代分析工具大大提高了我们评估抗体和试剂的品质和功能的能力，从而获得了更可重复和可靠的结果。此外，随着数位转型渗透到研究实验室，自动化和数据主导策略变得越来越普遍。业内公司目前正在使用高通量筛检和机器学习演算法来预测效能并优化生产流程。

此外，不断发展的法律规范和日益增长的严格临床验证需求已经开启了合规性和效率并存的时代。这些因素的融合使製造商能够满足未满足的需求并更有信心地预测未来趋势。随着对个人化医疗和客製化治疗的日益关注，该领域重新强调创新，这不仅满足当前的科学要求，而且为患者照护的突破铺平了道路。这种模式转移强化了市场对品质和进步的承诺，确保产品满足全球研究界的动态需求。

关键细分市场洞察与详细分析

市场区隔分析提供了抗体和试剂产业的全面视图，沿着多个轴线剖析市场并揭示对产品类型、技术流程和使用者需求的细緻见解。本研究首先按类型细分市场，将产品分为抗体和试剂，然后将抗体进一步分为原发性抗体、重组抗体和二抗。更具体地说，一抗分为单克隆和多克隆抗体类型，试剂涵盖广泛的产品，包括缓衝液和溶液、细胞培养试剂、细胞激素和生长因子、检测试剂、酶、固定剂和染色剂、核酸、探针、蛋白质和胜肽以及载体和质体。

透过分析抗体来源实现进一步细分，所调查的目标产品包括小鼠、兔子和大鼠来源的抗体，每种抗体都有不同的性能特征和特定应用的优势。技术分析方法包括酵素结合免疫吸附试验、流式细胞技术、萤光、免疫组织化学、免疫沉淀分析法、横向流动化验、质谱和西方墨点法。具体来说，酵素结合免疫吸附试验已被分为竞争性试验和夹心试验，以便更好地了解每种试验的贡献。

报告也根据疾病领域对临床疾病谱进行细分，涵盖循环系统、感染疾病、神经病学、肿瘤学等多种疾病。然后，每个大类又细分为具体疾病，例如循环系统中的动脉粥样硬化和高血压、感染疾病中的细菌和病毒感染、神经病学中的阿兹海默症症和帕金森氏症以及肿瘤学中的乳癌和肺癌。此外，我们也评估诊断、药物开发、研发（进一步分为基因组学和蛋白​​质组学）和治疗中的应用。最后，对市场最终用户的研究强调了学术研究机构、生物製药公司和受託研究机构之间的趋势。这种多层次的细分提供了综合的观点，对于明确市场机会和优化产品开发策略至关重要。

目录

第一章 引言

第二章调查方法

第三章执行摘要

第四章 市场概述

第五章 市场洞察

  • 市场动态
    • 驱动程式
      • 扩大政府抗体监测的资助倡议
      • 慢性病的日益普及推动了标靶抗体治疗方法的引入
      • 製药和生技公司研发支出持续增加
    • 限制因素
      • 生产研究抗体和试剂的初始成本较高
    • 机会
      • 加大对环保试剂的开发与采用
      • 抗体工程技术进步
    • 任务
      • 严格的监管要求，确保抗体和试剂的安全性和有效性
      • 关于抗体生产的伦理和生物学问题
  • 市场区隔分析
    • 类型：对执行和支持生化反应的试剂的需求不断增加
    • 最终用户：生物製药公司在药物发现和检验过程中越来越多地采用研究抗体和试剂。
  • 波特五力分析
  • PESTEL分析
    • 政治的
    • 经济
    • 社会
    • 技术的
    • 合法的
    • 环境

第六章研究抗体及试剂市场（按类型）

  • 抗体
    • 一抗
      • 单株抗体
      • 多株抗体
    • 重组抗体
    • 二抗
  • 试剂
    • 缓衝液和溶液
    • 细胞培养试剂
    • 细胞激素和生长因子
    • 检测试剂
    • 酵素
    • 稳定剂和染料
    • 核酸
    • 探测
    • 蛋白质和胜肽
    • 载体和质体

第七章。依来源研究抗体和试剂市场

  • 小鼠起源
  • 来自兔子
  • 大鼠起源

第八章研究抗体和试剂市场（按技术）

  • 酵素免疫分析法
    • 竞争分析
    • 夹心试验
  • 流式细胞技术
  • 萤光
  • 免疫组织化学
  • 免疫沉淀分析法
  • 横向流动化验
  • 质谱法
  • 西方印渍术

第九章 抗体及试剂市场（依疾病领域）研究

  • 心臟病学
    • 动脉硬化
    • 高血压
  • 感染疾病
    • 细菌感染疾病
    • 病毒感染
  • 神经病学
    • 阿兹海默症
    • 帕金森氏症
  • 肿瘤学
    • 乳癌
    • 肺癌

第 10 章研究抗体和试剂市场（按应用）

  • 诊断
  • 药物开发
  • 研究与开发
    • 基因组学
    • 蛋白质体学
  • 治疗

第 11 章研究抗体和试剂市场（依最终用户）

  • 学术研究所
  • 生物製药公司
  • 合约研究组织

12.美洲研究抗体与试剂市场

  • 阿根廷
  • 巴西
  • 加拿大
  • 墨西哥
  • 美国

13. 亚太地区监测抗体及试剂市场

  • 澳洲
  • 中国
  • 印度
  • 印尼
  • 日本
  • 马来西亚
  • 菲律宾
  • 新加坡
  • 韩国
  • 台湾
  • 泰国
  • 越南

14. 欧洲、中东和非洲研究抗体和试剂市场

  • 丹麦
  • 埃及
  • 芬兰
  • 法国
  • 德国
  • 以色列
  • 义大利
  • 荷兰
  • 奈及利亚
  • 挪威
  • 波兰
  • 卡达
  • 俄罗斯
  • 沙乌地阿拉伯
  • 南非
  • 西班牙
  • 瑞典
  • 瑞士
  • 土耳其
  • 阿拉伯聯合大公国
  • 英国

第十五章竞争格局

  • 2024年市场占有率分析
  • 2024年FPNV定位矩阵
  • 竞争情境分析
  • 战略分析与建议

公司名单

  • Abbott Laboratories
  • Agilent Technologies Inc.
  • Alpha Teknova, Inc.
  • Atlas Antibodies AB
  • Avantor, Inc.
  • BASF SE
  • Becton, Dickinson and Company
  • Bio-Rad Laboratories, Inc.
  • Bio-Techne Corporation
  • bioMerieux SA
  • Cardinal Health, Inc.
  • Cell Signaling Technology, Inc.
  • Charles River Laboratories International, Inc.
  • Danaher Corporation
  • Dovetail Genomics LLC
  • Enzo Life Sciences, Inc.
  • F. Hoffmann-La Roche Ltd.
  • FUJIFILM Holdings Corporation
  • GenScript Biotech Corporation
  • Honeywell International Inc.
  • Illumia, Inc.
  • ImmunoPrecise Antibodies Ltd.
  • Leinco Technologies, Inc.
  • LifeSpan BioSciences, Inc.
  • LobaChemie Pvt. Ltd.
  • Lonza Group Ltd.
  • Merck KGaA
  • Omega Bio-tek, Inc.
  • PerkinElmer, Inc.
  • QIAGEN NV
  • Randox Laboratories Ltd.
  • Rockland Immunochemicals, Inc.
  • Santa Cruz Biotechnology, Inc.
  • Sino Biological, Inc.
  • Thermo Fisher Scientific, Inc.
  • Tokyo Chemical Industry Co., Ltd.
  • Tosoh Corporation
Product Code: MRR-0D217D5AE090

The Research Antibodies & Reagents Market was valued at USD 18.55 billion in 2024 and is projected to grow to USD 20.79 billion in 2025, with a CAGR of 12.00%, reaching USD 36.62 billion by 2030.

KEY MARKET STATISTICS
Base Year [2024] USD 18.55 billion
Estimated Year [2025] USD 20.79 billion
Forecast Year [2030] USD 36.62 billion
CAGR (%) 12.00%

The field of antibodies and reagents continues to expand its impact on research, diagnostics, and therapeutics, driving forward innovation across numerous scientific disciplines. In recent years, the market has experienced a notable transformation fueled by technological advancements and urgent scientific demands, particularly in light of global health challenges. This comprehensive study is dedicated to exploring the intricate dynamics that shape the industry, shedding light on critical factors that influence market behavior and strategic decision-making.

As researchers and organizations strive for enhanced precision and reliability in their work, an increasing array of products and methodologies has emerged, offering greater specificity and reproducibility. The research underlying this summary delves into the product segmentation, technological breakthroughs, and evolving user demands, providing stakeholders with actionable insights that can be directly applied to their operational and strategic frameworks.

Drawing on data from rigorous market analysis and a wide spectrum of regional studies, the report sets the stage by contextualizing the current trends within a global framework. It emphasizes both the scientific and commercial aspects of development, highlighting the ways in which ongoing research efforts are tailored to meet the complex challenges of modern biomedical enquiry. This introduction paves the way for a deeper discussion of transformative market shifts and segmentation insights that are poised to influence the trajectory of the antibodies and reagents industry for years to come.

Transformative Shifts Redefining the Antibodies & Reagents Market

In an era marked by rapid technological change, the antibodies and reagents market is witnessing transformative shifts that are redefining both product development and market participation. The integration of cutting-edge technologies alongside traditional research methods has spurred innovation in areas such as recombinant engineering, formulation optimization, and advanced analytics. These developments are driving a significant change in the way products are created, evaluated, and ultimately deployed in both research and clinical environments.

Modern analytical tools have dramatically improved the ability to assess the quality and functionality of antibodies and reagents, leading to enhanced reproducibility and reliability of results. Moreover, as digital transformation permeates research laboratories, automation and data-driven strategies are becoming increasingly prevalent. Industry players are now leveraging high-throughput screening and machine learning algorithms to predict performance and optimize production processes.

Additionally, evolving regulatory frameworks and increasing demands for robust clinical validation have ushered in an era where compliance and efficiency go hand in hand. The blend of these factors is enabling manufacturers to address unmet needs and anticipate future trends more confidently. With an increased focus on personalized medicine and tailored therapeutics, the sector is experiencing a renewed emphasis on innovation that not only meets the current scientific requirements but also paves the way for breakthroughs in patient care. This paradigm shift reinforces the market's commitment to both quality and progress, ensuring that products align with the dynamic needs of a global research community.

Key Segmentation Insights and Detailed Analysis

The market segmentation analysis offers a comprehensive view of the antibodies and reagents industry, dissecting the market along multiple axes and revealing nuanced insights into product categories, technological processes, and user demands. The study initially segments the market on the basis of type by categorizing products into antibodies and reagents, where antibodies are further divided into primary antibodies, recombinant antibodies, and secondary antibodies. In greater detail, primary antibodies are classified into monoclonal and polyclonal types, while reagents cover a wide range of products such as buffers and solutions, cell culture reagents, cytokines and growth factors, detection reagents, enzymes, fixatives and stains, nucleic acids, probes, proteins and peptides, and vectors and plasmids.

Further segmentation is achieved by analyzing the source of antibodies, where products researched include those derived from mouse, rabbit, and rat origins, each offering distinct performance characteristics and application-specific advantages. The technological dimension of the analysis examines a portfolio of methodologies including enzyme-linked immunosorbent assay, flow cytometry, immunofluorescence, immunohistochemistry, immunoprecipitation, lateral flow assays, mass spectrometry, and Western blotting. Notably, the enzyme-linked immunosorbent assay is dissected further into competitive and sandwich assay formats to better understand their individual contributions.

The report also ventures into the clinical realm by segmenting based on disease area, covering diverse conditions like cardiology, infectious diseases, neurology, and oncology. Each of these broad categories is refined to include specific conditions such as atherosclerosis and hypertension under cardiology, bacterial and viral infections under infectious diseases, Alzheimer's and Parkinson's diseases under neurology, and breast and lung cancers under oncology. In addition, the analysis evaluates applications across diagnostics, drug development, research and development-which is further broken down into genomics and proteomics-and therapeutics. Finally, examining market end users reveals distinct trends in academic research institutions, biopharmaceutical companies, and contract research organizations. This multi-layered segmentation provides an integrated perspective that is essential for delineating market opportunities and optimizing product development strategies.

Based on Type, market is studied across Antibodies and Reagents. The Antibodies is further studied across Primary Antibodies, Recombinant Antibodies, and Secondary Antibodies. The Primary Antibodies is further studied across Monoclonal Antibodies and Polyclonal Antibodies. The Reagents is further studied across Buffers & Solutions, Cell Culture Reagents, Cytokines & Growth Factors, Detection Reagents, Enzymes, Fixatives & Stains, Nucleic Acids, Probes, Proteins & Peptides, and Vectors & Plasmids.

Based on Source, market is studied across Mouse-Derived, Rabbit-Derived, and Rat-Derived.

Based on Technology, market is studied across Enzyme-Linked Immunosorbent Assay, Flow Cytometry, Immunofluorescence, Immunohistochemistry, Immunoprecipitation, Lateral Flow Assays, Mass Spectrometry, and Western Blotting. The Enzyme-Linked Immunosorbent Assay is further studied across Competitive Assays and Sandwich Assays.

Based on Disease Area, market is studied across Cardiology, Infectious Diseases, Neurology, and Oncology. The Cardiology is further studied across Atherosclerosis and Hypertension. The Infectious Diseases is further studied across Bacterial Infections and Viral Infections. The Neurology is further studied across Alzheimer's Disease and Parkinson's Disease. The Oncology is further studied across Breast Cancer and Lung Cancer.

Based on Application, market is studied across Diagnostic, Drug Development, Research & Development, and Therapeutics. The Research & Development is further studied across Genomics and Proteomics.

Based on End User, market is studied across Academic Research Institutions, Biopharmaceutical Companies, and Contract Research Organizations.

Key Regional Insights Across Global Markets

Regional performance is critical to understanding how global disparities and localized advancements shape the antibodies and reagents market. Analysis of the Americas reveals a thriving ecosystem powered by significant investments in biotechnology, robust academic research infrastructures, and a high rate of regulatory approvals that foster innovation. The region stands out for its rapid adoption of advanced methodologies and a deep network of partnerships between public institutions and private enterprises.

Exploring the landscape in Europe, the Middle East and Africa demonstrates a blend of emerging research hubs and established centers of excellence. In these regions, governmental initiatives and increasing private sector investments are driving improvements in infrastructure and the acceleration of research and development activities. This diverse regional performance is further supported by a robust regulatory environment, which seeks to harmonize standards while encouraging innovation.

Meanwhile, the Asia-Pacific region is registering profound growth and dynamism. Fueled by escalating research expenditures, a burgeoning biopharmaceutical sector, and proactive governmental support, the region is rapidly becoming a nexus of innovation and experimentation. The confluence of traditional and modern research practices in Asia-Pacific creates a vibrant environment where scalability, cost-effectiveness, and technological sophistication converge to yield remarkable advancements in both product development and market penetration. Each of these regions presents unique opportunities and challenges, making them pivotal in shaping the overall trajectory of the global antibodies and reagents industry.

Based on Region, market is studied across Americas, Asia-Pacific, and Europe, Middle East & Africa. The Americas is further studied across Argentina, Brazil, Canada, Mexico, and United States. The United States is further studied across California, Florida, Illinois, New York, Ohio, Pennsylvania, and Texas. The Asia-Pacific is further studied across Australia, China, India, Indonesia, Japan, Malaysia, Philippines, Singapore, South Korea, Taiwan, Thailand, and Vietnam. The Europe, Middle East & Africa is further studied across Denmark, Egypt, Finland, France, Germany, Israel, Italy, Netherlands, Nigeria, Norway, Poland, Qatar, Russia, Saudi Arabia, South Africa, Spain, Sweden, Switzerland, Turkey, United Arab Emirates, and United Kingdom.

In-Depth Analysis of Leading Market Players

An examination of the competitive landscape underscores the importance of strategic alliances, technological investments, and continuous innovation. Several key industry players have solidified their presence through robust portfolios and extensive research and development pipelines. Companies such as Abbott Laboratories and Agilent Technologies Inc. have been at the forefront of offering high-quality research tools, while organizations like Alpha Teknova, Inc. and Atlas Antibodies AB have contributed significantly through specialized product offerings and niche expertise.

Leaders including Avantor, Inc. and BASF SE have capitalized on their expansive global networks to streamline supply chains and expand market reach. Similarly, Becton, Dickinson and Company alongside Bio-Rad Laboratories, Inc. have consistently pushed boundaries with innovative solutions that address a broad array of diagnostic and research needs. The role of Bio-Techne Corporation and bioMerieux S.A. in facilitating precision medicine and efficient diagnostic protocols illustrates the transformative impact of dedicated research initiatives.

Furthermore, companies such as Cardinal Health, Inc., Cell Signaling Technology, Inc., and Charles River Laboratories International, Inc. are renowned for their continuous pursuit of technological upgrades and product diversification. Industry giants such as Danaher Corporation and Dovetail Genomics LLC have harnessed the power of integrated systems to drive data-centric research approaches. This competitive panorama is further enriched by the contributions of Enzo Life Sciences, Inc., F. Hoffmann-La Roche Ltd., and FUJIFILM Holdings Corporation, whose strategic insights and investments in next-generation platforms are reshaping market dynamics.

Other notable contributors like GenScript Biotech Corporation, Honeywell International Inc., Illumia, Inc., and ImmunoPrecise Antibodies Ltd. continue to play pivotal roles in advancing research capabilities, while Leinco Technologies, Inc., LifeSpan BioSciences, Inc., and LobaChemie Pvt. Ltd. focus on delivering innovation through cost-effective solutions. Prominent entities such as Lonza Group Ltd., Merck KGaA, Omega Bio-tek, Inc., PerkinElmer, Inc., QIAGEN N.V., and Randox Laboratories Ltd. further highlight the diversity and depth of the market. The robust performance of these organizations, which includes leading figures like Rockland Immunochemicals, Inc., Santa Cruz Biotechnology, Inc., Sino Biological, Inc., Thermo Fisher Scientific, Inc., Tokyo Chemical Industry Co., Ltd., and Tosoh Corporation, solidifies a competitive framework where continuous evolution remains central to long-term success.

The report delves into recent significant developments in the Research Antibodies & Reagents Market, highlighting leading vendors and their innovative profiles. These include Abbott Laboratories, Agilent Technologies Inc., Alpha Teknova, Inc., Atlas Antibodies AB, Avantor, Inc., BASF SE, Becton, Dickinson and Company, Bio-Rad Laboratories, Inc., Bio-Techne Corporation, bioMerieux S.A., Cardinal Health, Inc., Cell Signaling Technology, Inc., Charles River Laboratories International, Inc., Danaher Corporation, Dovetail Genomics LLC, Enzo Life Sciences, Inc., F. Hoffmann-La Roche Ltd., FUJIFILM Holdings Corporation, GenScript Biotech Corporation, Honeywell International Inc., Illumia, Inc., ImmunoPrecise Antibodies Ltd., Leinco Technologies, Inc., LifeSpan BioSciences, Inc., LobaChemie Pvt. Ltd., Lonza Group Ltd., Merck KGaA, Omega Bio-tek, Inc., PerkinElmer, Inc., QIAGEN N.V., Randox Laboratories Ltd., Rockland Immunochemicals, Inc., Santa Cruz Biotechnology, Inc., Sino Biological, Inc., Thermo Fisher Scientific, Inc., Tokyo Chemical Industry Co., Ltd., and Tosoh Corporation. Strategic Recommendations for Industry Leaders

Industry leaders are encouraged to leverage the insights drawn from recent market trends to enhance operational efficiency and drive product innovation. It is essential to invest in advanced research technologies and data analytics to remain ahead in a rapidly evolving competitive landscape. Fostering cross-functional partnerships and aligning internal R&D with external scientific networks can also substantially increase market responsiveness and agility.

A clear focus on meeting regulatory requirements while simultaneously pushing the envelope in product customization and technological integration will fortify competitive positioning. Decision-makers are advised to consider strategic diversification, tailoring product lines to emerging market niches that span across various segmentation criteria. This includes not only investing in enhanced product development pipelines but also optimizing supply chain efficiencies to streamline production and distribution.

Embracing digital transformation by integrating advanced analytical tools and automation in the R&D process can lead to significant breakthroughs. Leaders must also pay attention to customer feedback, market demand fluctuations, and evolving industry practices to strategically position their portfolios for sustained growth.

Conclusive Reflections on Market Dynamics

The comprehensive evaluation of the antibodies and reagents market illustrates a sector on the cusp of continued transformation. Balancing the demands of cutting-edge research and regulatory compliance, the industry is experiencing robust growth driven by innovation and operational synergy. The dynamic interplay of technological advancement, diverse segmentation, and global regional insights has furnished stakeholders with a multidimensional perspective on both opportunities and challenges.

In essence, this analysis not only underscores the potential of advanced research methodologies and digital integrations but also highlights the critical need for agile strategies capable of addressing shifting market demands. The rigorous exploration into competitive landscapes and granular segmentation provides a clear outline of the paths available for both established players and new entrants. As the market continues to mature, the collective emphasis on quality, efficiency, and innovation will undoubtedly dictate future trends, ensuring that the sector remains resilient and responsive to emerging scientific challenges.

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Segmentation & Coverage
  • 1.3. Years Considered for the Study
  • 1.4. Currency & Pricing
  • 1.5. Language
  • 1.6. Stakeholders

2. Research Methodology

  • 2.1. Define: Research Objective
  • 2.2. Determine: Research Design
  • 2.3. Prepare: Research Instrument
  • 2.4. Collect: Data Source
  • 2.5. Analyze: Data Interpretation
  • 2.6. Formulate: Data Verification
  • 2.7. Publish: Research Report
  • 2.8. Repeat: Report Update

3. Executive Summary

4. Market Overview

5. Market Insights

  • 5.1. Market Dynamics
    • 5.1.1. Drivers
      • 5.1.1.1. Growing government funding initiatives for antibodies research purposes
      • 5.1.1.2. Rising prevalence of chronic diseases driving the adoption of targeted antibody-based treatments
      • 5.1.1.3. Continuous rise in research and development spending by pharmaceutical and biotechnology companies
    • 5.1.2. Restraints
      • 5.1.2.1. High initial costs associated with research antibodies and reagents production
    • 5.1.3. Opportunities
      • 5.1.3.1. Increasing development and adoption of environmentally friendly reagents
      • 5.1.3.2. Technological advancements in antibody engineering
    • 5.1.4. Challenges
      • 5.1.4.1. Stringent regulatory requirements to ensure the safety and efficacy of the antibodies and reagents
      • 5.1.4.2. Ethical and biological concerns over production of antibodies
  • 5.2. Market Segmentation Analysis
    • 5.2.1. Type: Rising demand for reagents for conducting and supporting biochemical reactions
    • 5.2.2. End user: Growing adoption of research antibodies & reagents across biopharmaceutical companies for drug discovery and validation processes.
  • 5.3. Porter's Five Forces Analysis
    • 5.3.1. Threat of New Entrants
    • 5.3.2. Threat of Substitutes
    • 5.3.3. Bargaining Power of Customers
    • 5.3.4. Bargaining Power of Suppliers
    • 5.3.5. Industry Rivalry
  • 5.4. PESTLE Analysis
    • 5.4.1. Political
    • 5.4.2. Economic
    • 5.4.3. Social
    • 5.4.4. Technological
    • 5.4.5. Legal
    • 5.4.6. Environmental

6. Research Antibodies & Reagents Market, by Type

  • 6.1. Introduction
  • 6.2. Antibodies
    • 6.2.1. Primary Antibodies
      • 6.2.1.1. Monoclonal Antibodies
      • 6.2.1.2. Polyclonal Antibodies
    • 6.2.2. Recombinant Antibodies
    • 6.2.3. Secondary Antibodies
  • 6.3. Reagents
    • 6.3.1. Buffers & Solutions
    • 6.3.2. Cell Culture Reagents
    • 6.3.3. Cytokines & Growth Factors
    • 6.3.4. Detection Reagents
    • 6.3.5. Enzymes
    • 6.3.6. Fixatives & Stains
    • 6.3.7. Nucleic Acids
    • 6.3.8. Probes
    • 6.3.9. Proteins & Peptides
    • 6.3.10. Vectors & Plasmids

7. Research Antibodies & Reagents Market, by Source

  • 7.1. Introduction
  • 7.2. Mouse-Derived
  • 7.3. Rabbit-Derived
  • 7.4. Rat-Derived

8. Research Antibodies & Reagents Market, by Technology

  • 8.1. Introduction
  • 8.2. Enzyme-Linked Immunosorbent Assay
    • 8.2.1. Competitive Assays
    • 8.2.2. Sandwich Assays
  • 8.3. Flow Cytometry
  • 8.4. Immunofluorescence
  • 8.5. Immunohistochemistry
  • 8.6. Immunoprecipitation
  • 8.7. Lateral Flow Assays
  • 8.8. Mass Spectrometry
  • 8.9. Western Blotting

9. Research Antibodies & Reagents Market, by Disease Area

  • 9.1. Introduction
  • 9.2. Cardiology
    • 9.2.1. Atherosclerosis
    • 9.2.2. Hypertension
  • 9.3. Infectious Diseases
    • 9.3.1. Bacterial Infections
    • 9.3.2. Viral Infections
  • 9.4. Neurology
    • 9.4.1. Alzheimer's Disease
    • 9.4.2. Parkinson's Disease
  • 9.5. Oncology
    • 9.5.1. Breast Cancer
    • 9.5.2. Lung Cancer

10. Research Antibodies & Reagents Market, by Application

  • 10.1. Introduction
  • 10.2. Diagnostic
  • 10.3. Drug Development
  • 10.4. Research & Development
    • 10.4.1. Genomics
    • 10.4.2. Proteomics
  • 10.5. Therapeutics

11. Research Antibodies & Reagents Market, by End User

  • 11.1. Introduction
  • 11.2. Academic Research Institutions
  • 11.3. Biopharmaceutical Companies
  • 11.4. Contract Research Organizations

12. Americas Research Antibodies & Reagents Market

  • 12.1. Introduction
  • 12.2. Argentina
  • 12.3. Brazil
  • 12.4. Canada
  • 12.5. Mexico
  • 12.6. United States

13. Asia-Pacific Research Antibodies & Reagents Market

  • 13.1. Introduction
  • 13.2. Australia
  • 13.3. China
  • 13.4. India
  • 13.5. Indonesia
  • 13.6. Japan
  • 13.7. Malaysia
  • 13.8. Philippines
  • 13.9. Singapore
  • 13.10. South Korea
  • 13.11. Taiwan
  • 13.12. Thailand
  • 13.13. Vietnam

14. Europe, Middle East & Africa Research Antibodies & Reagents Market

  • 14.1. Introduction
  • 14.2. Denmark
  • 14.3. Egypt
  • 14.4. Finland
  • 14.5. France
  • 14.6. Germany
  • 14.7. Israel
  • 14.8. Italy
  • 14.9. Netherlands
  • 14.10. Nigeria
  • 14.11. Norway
  • 14.12. Poland
  • 14.13. Qatar
  • 14.14. Russia
  • 14.15. Saudi Arabia
  • 14.16. South Africa
  • 14.17. Spain
  • 14.18. Sweden
  • 14.19. Switzerland
  • 14.20. Turkey
  • 14.21. United Arab Emirates
  • 14.22. United Kingdom

15. Competitive Landscape

  • 15.1. Market Share Analysis, 2024
  • 15.2. FPNV Positioning Matrix, 2024
  • 15.3. Competitive Scenario Analysis
    • 15.3.1. QIAGEN and McGill University partner to advance microbiome research
    • 15.3.2. UTMB awarded USD 46.4 million ReVAMPP grant for pandemic preparedness research
    • 15.3.3. Bio-Rad expands antibody range for enhanced bioanalytical assays
  • 15.4. Strategy Analysis & Recommendation

Companies Mentioned

  • 1. Abbott Laboratories
  • 2. Agilent Technologies Inc.
  • 3. Alpha Teknova, Inc.
  • 4. Atlas Antibodies AB
  • 5. Avantor, Inc.
  • 6. BASF SE
  • 7. Becton, Dickinson and Company
  • 8. Bio-Rad Laboratories, Inc.
  • 9. Bio-Techne Corporation
  • 10. bioMerieux S.A.
  • 11. Cardinal Health, Inc.
  • 12. Cell Signaling Technology, Inc.
  • 13. Charles River Laboratories International, Inc.
  • 14. Danaher Corporation
  • 15. Dovetail Genomics LLC
  • 16. Enzo Life Sciences, Inc.
  • 17. F. Hoffmann-La Roche Ltd.
  • 18. FUJIFILM Holdings Corporation
  • 19. GenScript Biotech Corporation
  • 20. Honeywell International Inc.
  • 21. Illumia, Inc.
  • 22. ImmunoPrecise Antibodies Ltd.
  • 23. Leinco Technologies, Inc.
  • 24. LifeSpan BioSciences, Inc.
  • 25. LobaChemie Pvt. Ltd.
  • 26. Lonza Group Ltd.
  • 27. Merck KGaA
  • 28. Omega Bio-tek, Inc.
  • 29. PerkinElmer, Inc.
  • 30. QIAGEN N.V.
  • 31. Randox Laboratories Ltd.
  • 32. Rockland Immunochemicals, Inc.
  • 33. Santa Cruz Biotechnology, Inc.
  • 34. Sino Biological, Inc.
  • 35. Thermo Fisher Scientific, Inc.
  • 36. Tokyo Chemical Industry Co., Ltd.
  • 37. Tosoh Corporation

LIST OF FIGURES

  • FIGURE 1. RESEARCH ANTIBODIES & REAGENTS MARKET MULTI-CURRENCY
  • FIGURE 2. RESEARCH ANTIBODIES & REAGENTS MARKET MULTI-LANGUAGE
  • FIGURE 3. RESEARCH ANTIBODIES & REAGENTS MARKET RESEARCH PROCESS
  • FIGURE 4. RESEARCH ANTIBODIES & REAGENTS MARKET SIZE, 2024 VS 2030
  • FIGURE 5. GLOBAL RESEARCH ANTIBODIES & REAGENTS MARKET SIZE, 2018-2030 (USD MILLION)
  • FIGURE 6. GLOBAL RESEARCH ANTIBODIES & REAGENTS MARKET SIZE, BY REGION, 2024 VS 2025 VS 2030 (USD MILLION)
  • FIGURE 7. GLOBAL RESEARCH ANTIBODIES & REAGENTS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
  • FIGURE 8. GLOBAL RESEARCH ANTIBODIES & REAGENTS MARKET SIZE, BY TYPE, 2024 VS 2030 (%)
  • FIGURE 9. GLOBAL RESEARCH ANTIBODIES & REAGENTS MARKET SIZE, BY TYPE, 2024 VS 2025 VS 2030 (USD MILLION)
  • FIGURE 10. GLOBAL RESEARCH ANTIBODIES & REAGENTS MARKET SIZE, BY SOURCE, 2024 VS 2030 (%)
  • FIGURE 11. GLOBAL RESEARCH ANTIBODIES & REAGENTS MARKET SIZE, BY SOURCE, 2024 VS 2025 VS 2030 (USD MILLION)
  • FIGURE 12. GLOBAL RESEARCH ANTIBODIES & REAGENTS MARKET SIZE, BY TECHNOLOGY, 2024 VS 2030 (%)
  • FIGURE 13. GLOBAL RESEARCH ANTIBODIES & REAGENTS MARKET SIZE, BY TECHNOLOGY, 2024 VS 2025 VS 2030 (USD MILLION)
  • FIGURE 14. GLOBAL RESEARCH ANTIBODIES & REAGENTS MARKET SIZE, BY DISEASE AREA, 2024 VS 2030 (%)
  • FIGURE 15. GLOBAL RESEARCH ANTIBODIES & REAGENTS MARKET SIZE, BY DISEASE AREA, 2024 VS 2025 VS 2030 (USD MILLION)
  • FIGURE 16. GLOBAL RESEARCH ANTIBODIES & REAGENTS MARKET SIZE, BY APPLICATION, 2024 VS 2030 (%)
  • FIGURE 17. GLOBAL RESEARCH ANTIBODIES & REAGENTS MARKET SIZE, BY APPLICATION, 2024 VS 2025 VS 2030 (USD MILLION)
  • FIGURE 18. GLOBAL RESEARCH ANTIBODIES & REAGENTS MARKET SIZE, BY END USER, 2024 VS 2030 (%)
  • FIGURE 19. GLOBAL RESEARCH ANTIBODIES & REAGENTS MARKET SIZE, BY END USER, 2024 VS 2025 VS 2030 (USD MILLION)
  • FIGURE 20. AMERICAS RESEARCH ANTIBODIES & REAGENTS MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
  • FIGURE 21. AMERICAS RESEARCH ANTIBODIES & REAGENTS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
  • FIGURE 22. UNITED STATES RESEARCH ANTIBODIES & REAGENTS MARKET SIZE, BY STATE, 2024 VS 2030 (%)
  • FIGURE 23. UNITED STATES RESEARCH ANTIBODIES & REAGENTS MARKET SIZE, BY STATE, 2024 VS 2025 VS 2030 (USD MILLION)
  • FIGURE 24. ASIA-PACIFIC RESEARCH ANTIBODIES & REAGENTS MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
  • FIGURE 25. ASIA-PACIFIC RESEARCH ANTIBODIES & REAGENTS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
  • FIGURE 26. EUROPE, MIDDLE EAST & AFRICA RESEARCH ANTIBODIES & REAGENTS MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
  • FIGURE 27. EUROPE, MIDDLE EAST & AFRICA RESEARCH ANTIBODIES & REAGENTS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
  • FIGURE 28. RESEARCH ANTIBODIES & REAGENTS MARKET SHARE, BY KEY PLAYER, 2024
  • FIGURE 29. RESEARCH ANTIBODIES & REAGENTS MARKET, FPNV POSITIONING MATRIX, 2024

LIST OF TABLES

  • TABLE 1. RESEARCH ANTIBODIES & REAGENTS MARKET SEGMENTATION & COVERAGE
  • TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2024
  • TABLE 3. GLOBAL RESEARCH ANTIBODIES & REAGENTS MARKET SIZE, 2018-2030 (USD MILLION)
  • TABLE 4. GLOBAL RESEARCH ANTIBODIES & REAGENTS MARKET SIZE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 5. GLOBAL RESEARCH ANTIBODIES & REAGENTS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 6. RESEARCH ANTIBODIES & REAGENTS MARKET DYNAMICS
  • TABLE 7. GLOBAL RESEARCH ANTIBODIES & REAGENTS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 8. GLOBAL RESEARCH ANTIBODIES & REAGENTS MARKET SIZE, BY ANTIBODIES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 9. GLOBAL RESEARCH ANTIBODIES & REAGENTS MARKET SIZE, BY PRIMARY ANTIBODIES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 10. GLOBAL RESEARCH ANTIBODIES & REAGENTS MARKET SIZE, BY MONOCLONAL ANTIBODIES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 11. GLOBAL RESEARCH ANTIBODIES & REAGENTS MARKET SIZE, BY POLYCLONAL ANTIBODIES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 12. GLOBAL RESEARCH ANTIBODIES & REAGENTS MARKET SIZE, BY PRIMARY ANTIBODIES, 2018-2030 (USD MILLION)
  • TABLE 13. GLOBAL RESEARCH ANTIBODIES & REAGENTS MARKET SIZE, BY RECOMBINANT ANTIBODIES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 14. GLOBAL RESEARCH ANTIBODIES & REAGENTS MARKET SIZE, BY SECONDARY ANTIBODIES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 15. GLOBAL RESEARCH ANTIBODIES & REAGENTS MARKET SIZE, BY ANTIBODIES, 2018-2030 (USD MILLION)
  • TABLE 16. GLOBAL RESEARCH ANTIBODIES & REAGENTS MARKET SIZE, BY REAGENTS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 17. GLOBAL RESEARCH ANTIBODIES & REAGENTS MARKET SIZE, BY BUFFERS & SOLUTIONS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 18. GLOBAL RESEARCH ANTIBODIES & REAGENTS MARKET SIZE, BY CELL CULTURE REAGENTS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 19. GLOBAL RESEARCH ANTIBODIES & REAGENTS MARKET SIZE, BY CYTOKINES & GROWTH FACTORS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 20. GLOBAL RESEARCH ANTIBODIES & REAGENTS MARKET SIZE, BY DETECTION REAGENTS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 21. GLOBAL RESEARCH ANTIBODIES & REAGENTS MARKET SIZE, BY ENZYMES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 22. GLOBAL RESEARCH ANTIBODIES & REAGENTS MARKET SIZE, BY FIXATIVES & STAINS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 23. GLOBAL RESEARCH ANTIBODIES & REAGENTS MARKET SIZE, BY NUCLEIC ACIDS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 24. GLOBAL RESEARCH ANTIBODIES & REAGENTS MARKET SIZE, BY PROBES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 25. GLOBAL RESEARCH ANTIBODIES & REAGENTS MARKET SIZE, BY PROTEINS & PEPTIDES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 26. GLOBAL RESEARCH ANTIBODIES & REAGENTS MARKET SIZE, BY VECTORS & PLASMIDS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 27. GLOBAL RESEARCH ANTIBODIES & REAGENTS MARKET SIZE, BY REAGENTS, 2018-2030 (USD MILLION)
  • TABLE 28. GLOBAL RESEARCH ANTIBODIES & REAGENTS MARKET SIZE, BY SOURCE, 2018-2030 (USD MILLION)
  • TABLE 29. GLOBAL RESEARCH ANTIBODIES & REAGENTS MARKET SIZE, BY MOUSE-DERIVED, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 30. GLOBAL RESEARCH ANTIBODIES & REAGENTS MARKET SIZE, BY RABBIT-DERIVED, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 31. GLOBAL RESEARCH ANTIBODIES & REAGENTS MARKET SIZE, BY RAT-DERIVED, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 32. GLOBAL RESEARCH ANTIBODIES & REAGENTS MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 33. GLOBAL RESEARCH ANTIBODIES & REAGENTS MARKET SIZE, BY ENZYME-LINKED IMMUNOSORBENT ASSAY, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 34. GLOBAL RESEARCH ANTIBODIES & REAGENTS MARKET SIZE, BY COMPETITIVE ASSAYS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 35. GLOBAL RESEARCH ANTIBODIES & REAGENTS MARKET SIZE, BY SANDWICH ASSAYS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 36. GLOBAL RESEARCH ANTIBODIES & REAGENTS MARKET SIZE, BY ENZYME-LINKED IMMUNOSORBENT ASSAY, 2018-2030 (USD MILLION)
  • TABLE 37. GLOBAL RESEARCH ANTIBODIES & REAGENTS MARKET SIZE, BY FLOW CYTOMETRY, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 38. GLOBAL RESEARCH ANTIBODIES & REAGENTS MARKET SIZE, BY IMMUNOFLUORESCENCE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 39. GLOBAL RESEARCH ANTIBODIES & REAGENTS MARKET SIZE, BY IMMUNOHISTOCHEMISTRY, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 40. GLOBAL RESEARCH ANTIBODIES & REAGENTS MARKET SIZE, BY IMMUNOPRECIPITATION, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 41. GLOBAL RESEARCH ANTIBODIES & REAGENTS MARKET SIZE, BY LATERAL FLOW ASSAYS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 42. GLOBAL RESEARCH ANTIBODIES & REAGENTS MARKET SIZE, BY MASS SPECTROMETRY, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 43. GLOBAL RESEARCH ANTIBODIES & REAGENTS MARKET SIZE, BY WESTERN BLOTTING, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 44. GLOBAL RESEARCH ANTIBODIES & REAGENTS MARKET SIZE, BY DISEASE AREA, 2018-2030 (USD MILLION)
  • TABLE 45. GLOBAL RESEARCH ANTIBODIES & REAGENTS MARKET SIZE, BY CARDIOLOGY, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 46. GLOBAL RESEARCH ANTIBODIES & REAGENTS MARKET SIZE, BY ATHEROSCLEROSIS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 47. GLOBAL RESEARCH ANTIBODIES & REAGENTS MARKET SIZE, BY HYPERTENSION, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 48. GLOBAL RESEARCH ANTIBODIES & REAGENTS MARKET SIZE, BY CARDIOLOGY, 2018-2030 (USD MILLION)
  • TABLE 49. GLOBAL RESEARCH ANTIBODIES & REAGENTS MARKET SIZE, BY INFECTIOUS DISEASES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 50. GLOBAL RESEARCH ANTIBODIES & REAGENTS MARKET SIZE, BY BACTERIAL INFECTIONS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 51. GLOBAL RESEARCH ANTIBODIES & REAGENTS MARKET SIZE, BY VIRAL INFECTIONS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 52. GLOBAL RESEARCH ANTIBODIES & REAGENTS MARKET SIZE, BY INFECTIOUS DISEASES, 2018-2030 (USD MILLION)
  • TABLE 53. GLOBAL RESEARCH ANTIBODIES & REAGENTS MARKET SIZE, BY NEUROLOGY, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 54. GLOBAL RESEARCH ANTIBODIES & REAGENTS MARKET SIZE, BY ALZHEIMER'S DISEASE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 55. GLOBAL RESEARCH ANTIBODIES & REAGENTS MARKET SIZE, BY PARKINSON'S DISEASE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 56. GLOBAL RESEARCH ANTIBODIES & REAGENTS MARKET SIZE, BY NEUROLOGY, 2018-2030 (USD MILLION)
  • TABLE 57. GLOBAL RESEARCH ANTIBODIES & REAGENTS MARKET SIZE, BY ONCOLOGY, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 58. GLOBAL RESEARCH ANTIBODIES & REAGENTS MARKET SIZE, BY BREAST CANCER, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 59. GLOBAL RESEARCH ANTIBODIES & REAGENTS MARKET SIZE, BY LUNG CANCER, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 60. GLOBAL RESEARCH ANTIBODIES & REAGENTS MARKET SIZE, BY ONCOLOGY, 2018-2030 (USD MILLION)
  • TABLE 61. GLOBAL RESEARCH ANTIBODIES & REAGENTS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 62. GLOBAL RESEARCH ANTIBODIES & REAGENTS MARKET SIZE, BY DIAGNOSTIC, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 63. GLOBAL RESEARCH ANTIBODIES & REAGENTS MARKET SIZE, BY DRUG DEVELOPMENT, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 64. GLOBAL RESEARCH ANTIBODIES & REAGENTS MARKET SIZE, BY RESEARCH & DEVELOPMENT, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 65. GLOBAL RESEARCH ANTIBODIES & REAGENTS MARKET SIZE, BY GENOMICS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 66. GLOBAL RESEARCH ANTIBODIES & REAGENTS MARKET SIZE, BY PROTEOMICS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 67. GLOBAL RESEARCH ANTIBODIES & REAGENTS MARKET SIZE, BY RESEARCH & DEVELOPMENT, 2018-2030 (USD MILLION)
  • TABLE 68. GLOBAL RESEARCH ANTIBODIES & REAGENTS MARKET SIZE, BY THERAPEUTICS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 69. GLOBAL RESEARCH ANTIBODIES & REAGENTS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 70. GLOBAL RESEARCH ANTIBODIES & REAGENTS MARKET SIZE, BY ACADEMIC RESEARCH INSTITUTIONS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 71. GLOBAL RESEARCH ANTIBODIES & REAGENTS MARKET SIZE, BY BIOPHARMACEUTICAL COMPANIES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 72. GLOBAL RESEARCH ANTIBODIES & REAGENTS MARKET SIZE, BY CONTRACT RESEARCH ORGANIZATIONS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 73. AMERICAS RESEARCH ANTIBODIES & REAGENTS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 74. AMERICAS RESEARCH ANTIBODIES & REAGENTS MARKET SIZE, BY ANTIBODIES, 2018-2030 (USD MILLION)
  • TABLE 75. AMERICAS RESEARCH ANTIBODIES & REAGENTS MARKET SIZE, BY PRIMARY ANTIBODIES, 2018-2030 (USD MILLION)
  • TABLE 76. AMERICAS RESEARCH ANTIBODIES & REAGENTS MARKET SIZE, BY REAGENTS, 2018-2030 (USD MILLION)
  • TABLE 77. AMERICAS RESEARCH ANTIBODIES & REAGENTS MARKET SIZE, BY SOURCE, 2018-2030 (USD MILLION)
  • TABLE 78. AMERICAS RESEARCH ANTIBODIES & REAGENTS MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 79. AMERICAS RESEARCH ANTIBODIES & REAGENTS MARKET SIZE, BY ENZYME-LINKED IMMUNOSORBENT ASSAY, 2018-2030 (USD MILLION)
  • TABLE 80. AMERICAS RESEARCH ANTIBODIES & REAGENTS MARKET SIZE, BY DISEASE AREA, 2018-2030 (USD MILLION)
  • TABLE 81. AMERICAS RESEARCH ANTIBODIES & REAGENTS MARKET SIZE, BY CARDIOLOGY, 2018-2030 (USD MILLION)
  • TABLE 82. AMERICAS RESEARCH ANTIBODIES & REAGENTS MARKET SIZE, BY INFECTIOUS DISEASES, 2018-2030 (USD MILLION)
  • TABLE 83. AMERICAS RESEARCH ANTIBODIES & REAGENTS MARKET SIZE, BY NEUROLOGY, 2018-2030 (USD MILLION)
  • TABLE 84. AMERICAS RESEARCH ANTIBODIES & REAGENTS MARKET SIZE, BY ONCOLOGY, 2018-2030 (USD MILLION)
  • TABLE 85. AMERICAS RESEARCH ANTIBODIES & REAGENTS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 86. AMERICAS RESEARCH ANTIBODIES & REAGENTS MARKET SIZE, BY RESEARCH & DEVELOPMENT, 2018-2030 (USD MILLION)
  • TABLE 87. AMERICAS RESEARCH ANTIBODIES & REAGENTS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 88. AMERICAS RESEARCH ANTIBODIES & REAGENTS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 89. ARGENTINA RESEARCH ANTIBODIES & REAGENTS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 90. ARGENTINA RESEARCH ANTIBODIES & REAGENTS MARKET SIZE, BY ANTIBODIES, 2018-2030 (USD MILLION)
  • TABLE 91. ARGENTINA RESEARCH ANTIBODIES & REAGENTS MARKET SIZE, BY PRIMARY ANTIBODIES, 2018-2030 (USD MILLION)
  • TABLE 92. ARGENTINA RESEARCH ANTIBODIES & REAGENTS MARKET SIZE, BY REAGENTS, 2018-2030 (USD MILLION)
  • TABLE 93. ARGENTINA RESEARCH ANTIBODIES & REAGENTS MARKET SIZE, BY SOURCE, 2018-2030 (USD MILLION)
  • TABLE 94. ARGENTINA RESEARCH ANTIBODIES & REAGENTS MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 95. ARGENTINA RESEARCH ANTIBODIES & REAGENTS MARKET SIZE, BY ENZYME-LINKED IMMUNOSORBENT ASSAY, 2018-2030 (USD MILLION)
  • TABLE 96. ARGENTINA RESEARCH ANTIBODIES & REAGENTS MARKET SIZE, BY DISEASE AREA, 2018-2030 (USD MILLION)
  • TABLE 97. ARGENTINA RESEARCH ANTIBODIES & REAGENTS MARKET SIZE, BY CARDIOLOGY, 2018-2030 (USD MILLION)
  • TABLE 98. ARGENTINA RESEARCH ANTIBODIES & REAGENTS MARKET SIZE, BY INFECTIOUS DISEASES, 2018-2030 (USD MILLION)
  • TABLE 99. ARGENTINA RESEARCH ANTIBODIES & REAGENTS MARKET SIZE, BY NEUROLOGY, 2018-2030 (USD MILLION)
  • TABLE 100. ARGENTINA RESEARCH ANTIBODIES & REAGENTS MARKET SIZE, BY ONCOLOGY, 2018-2030 (USD MILLION)
  • TABLE 101. ARGENTINA RESEARCH ANTIBODIES & REAGENTS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 102. ARGENTINA RESEARCH ANTIBODIES & REAGENTS MARKET SIZE, BY RESEARCH & DEVELOPMENT, 2018-2030 (USD MILLION)
  • TABLE 103. ARGENTINA RESEARCH ANTIBODIES & REAGENTS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 104. BRAZIL RESEARCH ANTIBODIES & REAGENTS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 105. BRAZIL RESEARCH ANTIBODIES & REAGENTS MARKET SIZE, BY ANTIBODIES, 2018-2030 (USD MILLION)
  • TABLE 106. BRAZIL RESEARCH ANTIBODIES & REAGENTS MARKET SIZE, BY PRIMARY ANTIBODIES, 2018-2030 (USD MILLION)
  • TABLE 107. BRAZIL RESEARCH ANTIBODIES & REAGENTS MARKET SIZE, BY REAGENTS, 2018-2030 (USD MILLION)
  • TABLE 108. BRAZIL RESEARCH ANTIBODIES & REAGENTS MARKET SIZE, BY SOURCE, 2018-2030 (USD MILLION)
  • TABLE 109. BRAZIL RESEARCH ANTIBODIES & REAGENTS MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 110. BRAZIL RESEARCH ANTIBODIES & REAGENTS MARKET SIZE, BY ENZYME-LINKED IMMUNOSORBENT ASSAY, 2018-2030 (USD MILLION)
  • TABLE 111. BRAZIL RESEARCH ANTIBODIES & REAGENTS MARKET SIZE, BY DISEASE AREA, 2018-2030 (USD MILLION)
  • TABLE 112. BRAZIL RESEARCH ANTIBODIES & REAGENTS MARKET SIZE, BY CARDIOLOGY, 2018-2030 (USD MILLION)
  • TABLE 113. BRAZIL RESEARCH ANTIBODIES & REAGENTS MARKET SIZE, BY INFECTIOUS DISEASES, 2018-2030 (USD MILLION)
  • TABLE 114. BRAZIL RESEARCH ANTIBODIES & REAGENTS MARKET SIZE, BY NEUROLOGY, 2018-2030 (USD MILLION)
  • TABLE 115. BRAZIL RESEARCH ANTIBODIES & REAGENTS MARKET SIZE, BY ONCOLOGY, 2018-2030 (USD MILLION)
  • TABLE 116. BRAZIL RESEARCH ANTIBODIES & REAGENTS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 117. BRAZIL RESEARCH ANTIBODIES & REAGENTS MARKET SIZE, BY RESEARCH & DEVELOPMENT, 2018-2030 (USD MILLION)
  • TABLE 118. BRAZIL RESEARCH ANTIBODIES & REAGENTS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 119. CANADA RESEARCH ANTIBODIES & REAGENTS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 120. CANADA RESEARCH ANTIBODIES & REAGENTS MARKET SIZE, BY ANTIBODIES, 2018-2030 (USD MILLION)
  • TABLE 121. CANADA RESEARCH ANTIBODIES & REAGENTS MARKET SIZE, BY PRIMARY ANTIBODIES, 2018-2030 (USD MILLION)
  • TABLE 122. CANADA RESEARCH ANTIBODIES & REAGENTS MARKET SIZE, BY REAGENTS, 2018-2030 (USD MILLION)
  • TABLE 123. CANADA RESEARCH ANTIBODIES & REAGENTS MARKET SIZE, BY SOURCE, 2018-2030 (USD MILLION)
  • TABLE 124. CANADA RESEARCH ANTIBODIES & REAGENTS MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 125. CANADA RESEARCH ANTIBODIES & REAGENTS MARKET SIZE, BY ENZYME-LINKED IMMUNOSORBENT ASSAY, 2018-2030 (USD MILLION)
  • TABLE 126. CANADA RESEARCH ANTIBODIES & REAGENTS MARKET SIZE, BY DISEASE AREA, 2018-2030 (USD MILLION)
  • TABLE 127. CANADA RESEARCH ANTIBODIES & REAGENTS MARKET SIZE, BY CARDIOLOGY, 2018-2030 (USD MILLION)
  • TABLE 128. CANADA RESEARCH ANTIBODIES & REAGENTS MARKET SIZE, BY INFECTIOUS DISEASES, 2018-2030 (USD MILLION)
  • TABLE 129. CANADA RESEARCH ANTIBODIES & REAGENTS MARKET SIZE, BY NEUROLOGY, 2018-2030 (USD MILLION)
  • TABLE 130. CANADA RESEARCH ANTIBODIES & REAGENTS MARKET SIZE, BY ONCOLOGY, 2018-2030 (USD MILLION)
  • TABLE 131. CANADA RESEARCH ANTIBODIES & REAGENTS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 132. CANADA RESEARCH ANTIBODIES & REAGENTS MARKET SIZE, BY RESEARCH & DEVELOPMENT, 2018-2030 (USD MILLION)
  • TABLE 133. CANADA RESEARCH ANTIBODIES & REAGENTS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 134. MEXICO RESEARCH ANTIBODIES & REAGENTS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 135. MEXICO RESEARCH ANTIBODIES & REAGENTS MARKET SIZE, BY ANTIBODIES, 2018-2030 (USD MILLION)
  • TABLE 136. MEXICO RESEARCH ANTIBODIES & REAGENTS MARKET SIZE, BY PRIMARY ANTIBODIES, 2018-2030 (USD MILLION)
  • TABLE 137. MEXICO RESEARCH ANTIBODIES & REAGENTS MARKET SIZE, BY REAGENTS, 2018-2030 (USD MILLION)
  • TABLE 138. MEXICO RESEARCH ANTIBODIES & REAGENTS MARKET SIZE, BY SOURCE, 2018-2030 (USD MILLION)
  • TABLE 139. MEXICO RESEARCH ANTIBODIES & REAGENTS MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 140. MEXICO RESEARCH ANTIBODIES & REAGENTS MARKET SIZE, BY ENZYME-LINKED IMMUNOSORBENT ASSAY, 2018-2030 (USD MILLION)
  • TABLE 141. MEXICO RESEARCH ANTIBODIES & REAGENTS MARKET SIZE, BY DISEASE AREA, 2018-2030 (USD MILLION)
  • TABLE 142. MEXICO RESEARCH ANTIBODIES & REAGENTS MARKET SIZE, BY CARDIOLOGY, 2018-2030 (USD MILLION)
  • TABLE 143. MEXICO RESEARCH ANTIBODIES & REAGENTS MARKET SIZE, BY INFECTIOUS DISEASES, 2018-2030 (USD MILLION)
  • TABLE 144. MEXICO RESEARCH ANTIBODIES & REAGENTS MARKET SIZE, BY NEUROLOGY, 2018-2030 (USD MILLION)
  • TABLE 145. MEXICO RESEARCH ANTIBODIES & REAGENTS MARKET SIZE, BY ONCOLOGY, 2018-2030 (USD MILLION)
  • TABLE 146. MEXICO RESEARCH ANTIBODIES & REAGENTS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 147. MEXICO RESEARCH ANTIBODIES & REAGENTS MARKET SIZE, BY RESEARCH & DEVELOPMENT, 2018-2030 (USD MILLION)
  • TABLE 148. MEXICO RESEARCH ANTIBODIES & REAGENTS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 149. UNITED STATES RESEARCH ANTIBODIES & REAGENTS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 150. UNITED STATES RESEARCH ANTIBODIES & REAGENTS MARKET SIZE, BY ANTIBODIES, 2018-2030 (USD MILLION)
  • TABLE 151. UNITED STATES RESEARCH ANTIBODIES & REAGENTS MARKET SIZE, BY PRIMARY ANTIBODIES, 2018-2030 (USD MILLION)
  • TABLE 152. UNITED STATES RESEARCH ANTIBODIES & REAGENTS MARKET SIZE, BY REAGENTS, 2018-2030 (USD MILLION)
  • TABLE 153. UNITED STATES RESEARCH ANTIBODIES & REAGENTS MARKET SIZE, BY SOURCE, 2018-2030 (USD MILLION)
  • TABLE 154. UNITED STATES RESEARCH ANTIBODIES & REAGENTS MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 155. UNITED STATES RESEARCH ANTIBODIES & REAGENTS MARKET SIZE, BY ENZYME-LINKED IMMUNOSORBENT ASSAY, 2018-2030 (USD MILLION)
  • TABLE 156. UNITED STATES RESEARCH ANTIBODIES & REAGENTS MARKET SIZE, BY DISEASE AREA, 2018-2030 (USD MILLION)
  • TABLE 157. UNITED STATES RESEARCH ANTIBODIES & REAGENTS MARKET SIZE, BY CARDIOLOGY, 2018-2030 (USD MILLION)
  • TABLE 158. UNITED STATES RESEARCH ANTIBODIES & REAGENTS MARKET SIZE, BY INFECTIOUS DISEASES, 2018-2030 (USD MILLION)
  • TABLE 159. UNITED STATES RESEARCH ANTIBODIES & REAGENTS MARKET SIZE, BY NEUROLOGY, 2018-2030 (USD MILLION)
  • TABLE 160. UNITED STATES RESEARCH ANTIBODIES & REAGENTS MARKET SIZE, BY ONCOLOGY, 2018-2030 (USD MILLION)
  • TABLE 161. UNITED STATES RESEARCH ANTIBODIES & REAGENTS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 162. UNITED STATES RESEARCH ANTIBODIES & REAGENTS MARKET SIZE, BY RESEARCH & DEVELOPMENT, 2018-2030 (USD MILLION)
  • TABLE 163. UNITED STATES RESEARCH ANTIBODIES & REAGENTS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 164. UNITED STATES RESEARCH ANTIBODIES & REAGENTS MARKET SIZE, BY STATE, 2018-2030 (USD MILLION)
  • TABLE 165. ASIA-PACIFIC RESEARCH ANTIBODIES & REAGENTS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 166. ASIA-PACIFIC RESEARCH ANTIBODIES & REAGENTS MARKET SIZE, BY ANTIBODIES, 2018-2030 (USD MILLION)
  • TABLE 167. ASIA-PACIFIC RESEARCH ANTIBODIES & REAGENTS MARKET SIZE, BY PRIMARY ANTIBODIES, 2018-2030 (USD MILLION)
  • TABLE 168. ASIA-PACIFIC RESEARCH ANTIBODIES & REAGENTS MARKET SIZE, BY REAGENTS, 2018-2030 (USD MILLION)
  • TABLE 169. ASIA-PACIFIC RESEARCH ANTIBODIES & REAGENTS MARKET SIZE, BY SOURCE, 2018-2030 (USD MILLION)
  • TABLE 170. ASIA-PACIFIC RESEARCH ANTIBODIES & REAGENTS MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 171. ASIA-PACIFIC RESEARCH ANTIBODIES & REAGENTS MARKET SIZE, BY ENZYME-LINKED IMMUNOSORBENT ASSAY, 2018-2030 (USD MILLION)
  • TABLE 172. ASIA-PACIFIC RESEARCH ANTIBODIES & REAGENTS MARKET SIZE, BY DISEASE AREA, 2018-2030 (USD MILLION)
  • TABLE 173. ASIA-PACIFIC RESEARCH ANTIBODIES & REAGENTS MARKET SIZE, BY CARDIOLOGY, 2018-2030 (USD MILLION)
  • TABLE 174. ASIA-PACIFIC RESEARCH ANTIBODIES & REAGENTS MARKET SIZE, BY INFECTIOUS DISEASES, 2018-2030 (USD MILLION)
  • TABLE 175. ASIA-PACIFIC RESEARCH ANTIBODIES & REAGENTS MARKET SIZE, BY NEUROLOGY, 2018-2030 (USD MILLION)
  • TABLE 176. ASIA-PACIFIC RESEARCH ANTIBODIES & REAGENTS MARKET SIZE, BY ONCOLOGY, 2018-2030 (USD MILLION)
  • TABLE 177. ASIA-PACIFIC RESEARCH ANTIBODIES & REAGENTS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 178. ASIA-PACIFIC RESEARCH ANTIBODIES & REAGENTS MARKET SIZE, BY RESEARCH & DEVELOPMENT, 2018-2030 (USD MILLION)
  • TABLE 179. ASIA-PACIFIC RESEARCH ANTIBODIES & REAGENTS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 180. ASIA-PACIFIC RESEARCH ANTIBODIES & REAGENTS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 181. AUSTRALIA RESEARCH ANTIBODIES & REAGENTS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 182. AUSTRALIA RESEARCH ANTIBODIES & REAGENTS MARKET SIZE, BY ANTIBODIES, 2018-2030 (USD MILLION)
  • TABLE 183. AUSTRALIA RESEARCH ANTIBODIES & REAGENTS MARKET SIZE, BY PRIMARY ANTIBODIES, 2018-2030 (USD MILLION)
  • TABLE 184. AUSTRALIA RESEARCH ANTIBODIES & REAGENTS MARKET SIZE, BY REAGENTS, 2018-2030 (USD MILLION)
  • TABLE 185. AUSTRALIA RESEARCH ANTIBODIES & REAGENTS MARKET SIZE, BY SOURCE, 2018-2030 (USD MILLION)
  • TABLE 186. AUSTRALIA RESEARCH ANTIBODIES & REAGENTS MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 187. AUSTRALIA RESEARCH ANTIBODIES & REAGENTS MARKET SIZE, BY ENZYME-LINKED IMMUNOSORBENT ASSAY, 2018-2030 (USD MILLION)
  • TABLE 188. AUSTRALIA RESEARCH ANTIBODIES & REAGENTS MARKET SIZE, BY DISEASE AREA, 2018-2030 (USD MILLION)
  • TABLE 189. AUSTRALIA RESEARCH ANTIBODIES & REAGENTS MARKET SIZE, BY CARDIOLOGY, 2018-2030 (USD MILLION)
  • TABLE 190. AUSTRALIA RESEARCH ANTIBODIES & REAGENTS MARKET SIZE, BY INFECTIOUS DISEASES, 2018-2030 (USD MILLION)
  • TABLE 191. AUSTRALIA RESEARCH ANTIBODIES & REAGENTS MARKET SIZE, BY NEUROLOGY, 2018-2030 (USD MILLION)
  • TABLE 192. AUSTRALIA RESEARCH ANTIBODIES & REAGENTS MARKET SIZE, BY ONCOLOGY, 2018-2030 (USD MILLION)
  • TABLE 193. AUSTRALIA RESEARCH ANTIBODIES & REAGENTS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 194. AUSTRALIA RESEARCH ANTIBODIES & REAGENTS MARKET SIZE, BY RESEARCH & DEVELOPMENT, 2018-2030 (USD MILLION)
  • TABLE 195. AUSTRALIA RESEARCH ANTIBODIES & REAGENTS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 196. CHINA RESEARCH ANTIBODIES & REAGENTS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 197. CHINA RESEARCH ANTIBODIES & REAGENTS MARKET SIZE, BY ANTIBODIES, 2018-2030 (USD MILLION)
  • TABLE 198. CHINA RESEARCH ANTIBODIES & REAGENTS MARKET SIZE, BY PRIMARY ANTIBODIES, 2018-2030 (USD MILLION)
  • TABLE 199. CHINA RESEARCH ANTIBODIES & REAGENTS MARKET SIZE, BY REAGENTS, 2018-2030 (USD MILLION)
  • TABLE 200. CHINA RESEARCH ANTIBODIES & REAGENTS MARKET SIZE, BY SOURCE, 2018-2030 (USD MILLION)
  • TABLE 201. CHINA RESEARCH ANTIBODIES & REAGENTS MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 202. CHINA RESEARCH ANTIBODIES & REAGENTS MARKET SIZE, BY ENZYME-LINKED IMMUNOSORBENT ASSAY, 2018-2030 (USD MILLION)
  • TABLE 203. CHINA RESEARCH ANTIBODIES & REAGENTS MARKET SIZE, BY DISEASE AREA, 2018-2030 (USD MILLION)
  • TABLE 204. CHINA RESEARCH ANTIBODIES & REAGENTS MARKET SIZE, BY CARDIOLOGY, 2018-2030 (USD MILLION)
  • TABLE 205. CHINA RESEARCH ANTIBODIES & REAGENTS MARKET SIZE, BY INFECTIOUS DISEASES, 2018-2030 (USD MILLION)
  • TABLE 206. CHINA RESEARCH ANTIBODIES & REAGENTS MARKET SIZE, BY NEUROLOGY, 2018-2030 (USD MILLION)
  • TABLE 207. CHINA RESEARCH ANTIBODIES & REAGENTS MARKET SIZE, BY ONCOLOGY, 2018-2030 (USD MILLION)
  • TABLE 208. CHINA RESEARCH ANTIBODIES & REAGENTS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 209. CHINA RESEARCH ANTIBODIES & REAGENTS MARKET SIZE, BY RESEARCH & DEVELOPMENT, 2018-2030 (USD MILLION)
  • TABLE 210. CHINA RESEARCH ANTIBODIES & REAGENTS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 211. INDIA RESEARCH ANTIBODIES & REAGENTS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 212. INDIA RESEARCH ANTIBODIES & REAGENTS MARKET SIZE, BY ANTIBODIES, 2018-2030 (USD MILLION)
  • TABLE 213. INDIA RESEARCH ANTIBODIES & REAGENTS MARKET SIZE, BY PRIMARY ANTIBODIES, 2018-2030 (USD MILLION)
  • TABLE 214. INDIA RESEARCH ANTIBODIES & REAGENTS MARKET SIZE, BY REAGENTS, 2018-2030 (USD MILLION)
  • TABLE 215. INDIA RESEARCH ANTIBODIES & REAGENTS MARKET SIZE, BY SOURCE, 2018-2030 (USD MILLION)
  • TABLE 216. INDIA RESEARCH ANTIBODIES & REAGENTS MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 217. INDIA RESEARCH ANTIBODIES & REAGENTS MARKET SIZE, BY ENZYME-LINKED IMMUNOSORBENT ASSAY, 2018-2030 (USD MILLION)
  • TABLE 218. INDIA RESEARCH ANTIBODIES & REAGENTS MARKET SIZE, BY DISEASE AREA, 2018-2030 (USD MILLION)
  • TABLE 219. INDIA RESEARCH ANTIBODIES & REAGENTS MARKET SIZE, BY CARDIOLOGY, 2018-2030 (USD MILLION)
  • TABLE 220. INDIA RESEARCH ANTIBODIES & REAGENTS MARKET SIZE, BY INFECTIOUS DISEASES, 2018-2030 (USD MILLION)
  • TABLE 221. INDIA RESEARCH ANTIBODIES & REAGENTS MARKET SIZE, BY NEUROLOGY, 2018-2030 (USD MILLION)
  • TABLE 222. INDIA RESEARCH ANTIBODIES & REAGENTS MARKET SIZE, BY ONCOLOGY, 2018-2030 (USD MILLION)
  • TABLE 223. INDIA RESEARCH ANTIBODIES & REAGENTS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 224. INDIA RESEARCH ANTIBODIES & REAGENTS MARKET SIZE, BY RESEARCH & DEVELOPMENT, 2018-2030 (USD MILLION)
  • TABLE 225. INDIA RESEARCH ANTIBODIES & REAGENTS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 226. INDONESIA RESEARCH ANTIBODIES & REAGENTS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 227. INDONESIA RESEARCH ANTIBODIES & REAGENTS MARKET SIZE, BY ANTIBODIES, 2018-2030 (USD MILLION)
  • TABLE 228. INDONESIA RESEARCH ANTIBODIES & REAGENTS MARKET SIZE, BY PRIMARY ANTIBODIES, 2018-2030 (USD MILLION)
  • TABLE 229. INDONESIA RESEARCH ANTIBODIES & REAGENTS MARKET SIZE, BY REAGENTS, 2018-2030 (USD MILLION)
  • TABLE 230. INDONESIA RESEARCH ANTIBODIES & REAGENTS MARKET SIZE, BY SOURCE, 2018-2030 (USD MILLION)
  • TABLE 231. INDONESIA RESEARCH ANTIBODIES & REAGENTS MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 232. INDONESIA RESEARCH ANTIBODIES & REAGENTS MARKET SIZE, BY ENZYME-LINKED IMMUNOSORBENT ASSAY, 2018-2030 (USD MILLION)
  • TABLE 233. INDONESIA RESEARCH ANTIBODIES & REAGENTS MARKET SIZE, BY DISEASE AREA, 2018-2030 (USD MILLION)
  • TABLE 234. INDONESIA RESEARCH ANTIBODIES & REAGENTS MARKET SIZE, BY CARDIOLOGY, 2018-2030 (USD MILLION)
  • TABLE 235. INDONESIA RESEARCH ANTIBODIES & REAGENTS MARKET SIZE, BY INFECTIOUS DISEASES, 2018-2030 (USD MILLION)
  • TABLE 236. INDONESIA RESEARCH ANTIBODIES & REAGENTS MARKET SIZE, BY NEUROLOGY, 2018-2030 (USD MILLION)
  • TABLE 237. INDONESIA RESEARCH ANTIBODIES & REAGENTS MARKET SIZE, BY ONCOLOGY, 2018-2030 (USD MILLION)
  • TABLE 238. INDONESIA RESEARCH ANTIBODIES & REAGENTS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 239. INDONESIA RESEARCH ANTIBODIES & REAGENTS MARKET SIZE, BY RESEARCH & DEVELOPMENT, 2018-2030 (USD MILLION)
  • TABLE 240. INDONESIA RESEARCH ANTIBODIES & REAGENTS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 241. JAPAN RESEARCH ANTIBODIES & REAGENTS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 242. JAPAN RESEARCH ANTIBODIES & REAGENTS MARKET SIZE, BY ANTIBODIES, 2018-2030 (USD MILLION)
  • TABLE 243. JAPAN RESEARCH ANTIBODIES & REAGENTS MARKET SIZE, BY PRIMARY ANTIBODIES, 2018-2030 (USD MILLION)
  • TABLE 244. JAPAN RESEARCH ANTIBODIES & REAGENTS MARKET SIZE, BY REAGENTS, 2018-2030 (USD MILLION)
  • TABLE 245. JAPAN RESEARCH ANTIBODIES & REAGENTS MARKET SIZE, BY SOURCE, 2018-2030 (USD MILLION)
  • TABLE 246. JAPAN RESEARCH ANTIBODIES & REAGENTS MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 247. JAPAN RESEARCH ANTIBODIES & REAGENTS MARKET SIZE, BY ENZYME-LINKED IMMUNOSORBENT ASSAY, 2018-2030 (USD MILLION)
  • TABLE 248. JAPAN RESEARCH ANTIBODIES & REAGENTS MARKET SIZE, BY DISEASE AREA, 2018-2030 (USD MILLION)
  • TABLE 249. JAPAN RESEARCH ANTIBODIES & REAGENTS MARKET SIZE, BY CARDIOLOGY, 2018-2030 (USD MILLION)
  • TABLE 250. JAPAN RESEARCH ANTIBODIES & REAGENTS MARKET SIZE, BY INFECTIOUS DISEASES, 2018-2030 (USD MILLION)
  • TABLE 251. JAPAN RESEARCH ANTIBODIES & REAGENTS MARKET SIZE, BY NEUROLOGY, 2018-2030 (USD MILLION)
  • TABLE 252. JAPAN RESEARCH ANTIBODIES & REAGENTS MARKET SIZE, BY ONCOLOGY, 2018-2030 (USD MILLION)
  • TABLE 253. JAPAN RESEARCH ANTIBODIES & REAGENTS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 254. JAPAN RESEARCH ANTIBODIES & REAGENTS MARKET SIZE, BY RESEARCH & DEVELOPMENT, 2018-2030 (USD MILLION)
  • TABLE 255. JAPAN RESEARCH ANTIBODIES & REAGENTS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 256. MALAYSIA RESEARCH ANTIBODIES & REAGENTS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 257. MALAYSIA RESEARCH ANTIBODIES & REAGENTS MARKET SIZE, BY ANTIBODIES, 2018-2030 (USD MILLION)
  • TABLE 258. MALAYSIA RESEARCH ANTIBODIES & REAGENTS MARKET SIZE, BY PRIMARY ANTIBODIES, 2018-2030 (USD MILLION)
  • TABLE 259. MALAYSIA RESEARCH ANTIBODIES & REAGENTS MARKET SIZE, BY REAGENTS, 2018-2030 (USD MILLION)
  • TABLE 260. MALAYSIA RESEARCH ANTIBODIES & REAGENTS MARKET SIZE, BY SOURCE, 2018-2030 (USD MILLION)
  • TABLE 261. MALAYSIA RESEARCH ANTIBODIES & REAGENTS MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 262. MALAYSIA RESEARCH ANTIBODIES & REAGENTS MARKET SIZE, BY ENZYME-LINKED IMMUNOSORBENT ASSAY, 2018-2030 (USD MILLION)
  • TABLE 263. MALAYSIA RESEARCH ANTIBODIES & REAGENTS MARKET SIZE, BY DISEASE AREA, 2018-2030 (USD MILLION)
  • TABLE 264. MALAYSIA RESEARCH ANTIBODIES & REAGENTS MARKET SIZE, BY CARDIOLOGY, 2018-2030 (USD MILLION)
  • TABLE 265. MALAYSIA RESEARCH ANTIBODIES & REAGENTS MARKET SIZE, BY INFECTIOUS DISEASES, 2018-2030 (USD MILLION)
  • TABLE 266. MALAYSIA RESEARCH ANTIBODIES & REAGENTS MARKET SIZE, BY NEUROLOGY, 2018-2030 (USD MILLION)
  • TABLE 267. MALAYSIA RESEARCH ANTIBODIES & REAGENTS MARKET SIZE, BY ONCOLOGY, 2018-2030 (USD MILLION)
  • TABLE 268. MALAYSIA RESEARCH ANTIBODIES & REAGENTS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 269. MALAYSIA RESEARCH ANTIBODIES & REAGENTS MARKET SIZE, BY RESEARCH & DEVELOPMENT, 2018-2030 (USD MILLION)
  • TABLE 270. MALAYSIA RESEARCH ANTIBODIES & REAGENTS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 271. PHILIPPINES RESEARCH ANTIBODIES & REAGENTS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 272. PHILIPPINES RESEARCH ANTIBODIES & REAGENTS MARKET SIZE, BY ANTIBODIES, 2018-2030 (USD MILLION)
  • TABLE 273. PHILIPPINES RESEARCH ANTIBODIES & REAGENTS MARKET SIZE, BY PRIMARY ANTIBODIES, 2018-2030 (USD MILLION)
  • TABLE 274. PHILIPPINES RESEARCH ANTIBODIES & REAGENTS MARKET SIZE, BY REAGENTS, 2018-2030 (USD MILLION)
  • TABLE 275. PHILIPPINES RESEARCH ANTIBODIES & REAGENTS MARKET SIZE, BY SOURCE, 2018-2030 (USD MILLION)
  • TABLE 276. PHILIPPINES RESEARCH ANTIBODIES & REAGENTS MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 277. PHILIPPINES RESEARCH ANTIBODIES & REAGENTS MARKET SIZE, BY ENZYME-LINKED IMMUNOSORBENT ASSAY, 2018-2030 (USD MILLION)
  • TABLE 278. PHILIPPINES RESEARCH ANTIBODIES & REAGENTS MARKET SIZE, BY DISEASE AREA, 2018-2030 (USD MILLION)
  • TABLE 279. PHILIPPINES RESEARCH ANTIBODIES & REAGENTS MARKET SIZE, BY CARDIOLOGY, 2018-2030 (USD MILLION)
  • TABLE 280. PHILIPPINES RESEARCH ANTIBODIES & REAGENTS MARKET SIZE, BY INFECTIOUS DISEASES, 2018-2030 (USD MILLION)
  • TABLE 281. PHILIPPINES RESEARCH ANTIBODIES & REAGENTS MARKET SIZE, BY NEUROLOGY, 2018-2030 (USD MILLION)
  • TABLE 282. PHILIPPINES RESEARCH ANTIBODIES & REAGENTS MARKET SIZE, BY ONCOLOGY, 2018-2030 (USD MILLION)
  • TABLE 283. PHILIPPINES RESEARCH ANTIBODIES & REAGENTS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 284. PHILIPPINES RESEARCH ANTIBODIES & REAGENTS MARKET SIZE, BY RESEARCH & DEVELOPMENT, 2018-2030 (USD MILLION)
  • TABLE 285. PHILIPPINES RESEARCH ANTIBODIES & REAGENTS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 286. SINGAPORE RESEARCH ANTIBODIES & REAGENTS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 287. SINGAPORE RESEARCH ANTIBODIES & REAGENTS MARKET SIZE, BY ANTIBODIES, 2018-2030 (USD MILLION)
  • TABLE 288. SINGAPORE RESEARCH ANTIBODIES & REAGENTS MARKET SIZE, BY PRIMARY ANTIBODIES, 2018-2030 (USD MILLION)
  • TABLE 289. SINGAPORE RESEARCH ANTIBODIES & REAGENTS MARKET SIZE, BY REAGENTS, 2018-2030 (USD MILLION)
  • TABLE 290. SINGAPORE RESEARCH ANTIBODIES & REAGENTS MARKET SIZE, BY SOURCE, 2018-2030 (USD MILLION)
  • TABLE 291. SINGAPORE RESEARCH ANTIBODIES & REAGENTS MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 292. SINGAPORE RESEARCH ANTIBODIES & REAGENTS MARKET SIZE, BY ENZYME-LINKED IMMUNOSORBENT ASSAY, 2018-2030 (USD MILLION)
  • TABLE 293. SINGAPORE RESEARCH ANTIBODIES & REAGENTS MARKET SIZE, BY DISEASE AREA, 2018-2030 (USD MILLION)
  • TABLE 294. SINGAPORE RESEARCH ANTIBODIES & REAGENTS MARKET SIZE, BY CARDIOLOGY, 2018-2030 (USD MILLION)
  • TABLE 295. SINGAPORE RESEARCH ANTIBODIES & REAGENTS MARKET SIZE, BY INFECTIOUS DISEASES, 2018-2030 (USD MILLION)
  • TABLE 296. SINGAPORE RESEARCH ANTIBODIES & REAGENTS MARKET SIZE, BY NEUROLOGY, 2018-2030 (USD MILLION)
  • TABLE 297. SINGAPORE RESEARCH ANTIBODIES & REAGENTS MARKET SIZE, BY ONCOLOGY, 2018-2030 (USD MILLION)
  • TABLE 298. SINGAPORE RESEARCH ANTIBODIES & REAGENTS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 299. SINGAPORE RESEARCH ANTIBODIES & REAGENTS MARKET SIZE, BY RESEARCH & DEVELOPMENT, 2018-2030 (USD MILLION)
  • TABLE 300. SINGAPORE RESEARCH ANTIBODIES & REAGENTS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 301. SOUTH KOREA RESEARCH ANTIBODIES & REAGENTS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 302. SOUTH KOREA RESEARCH ANTIBODIES & REAGENTS MARKET SIZE, BY ANTIBODIES, 2018-2030 (USD MILLION)
  • TABLE 303. SOUTH KOREA RESEARCH ANTIBODIES & REAGENTS MARKET SIZE, BY PRIMARY ANTIBODIES, 2018-2030 (USD MILLION)
  • TABLE 304. SOUTH KOREA RESEARCH ANTIBODIES & REAGENTS MARKET SIZE, BY REAGENTS, 2018-2030 (USD MILLION)
  • TABLE 305. SOUTH KOREA RESEARCH ANTIBODIES & REAGENTS MARKET SIZE, BY SOURCE, 2018-2030 (USD MILLION)
  • TABLE 306. SOUTH KOREA RESEARCH ANTIBODIES & REAGENTS MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 307. SOUTH KOREA RESEARCH ANTIBODIES & REAGENTS MARKET SIZE, BY ENZYME-LINKED IMMUNOSORBENT ASS